Haemonetics Corp.’s (HAE) share price has entered into oversold territory with a stochastic value of 19.55. Analysts have been increasing their estimates on the company’s full-year earnings, sending the Zacks Consensus Estimate up a penny over the past 2 months to $2.81 per share. Haemonetics is a Zacks #2 Rank (“Buy”) company.
“HAE” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research